A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: Preliminary trial

Clinical and Experimental Nephrology

Volumn 7, Issue 1, 2003, Pages 48-51

  Kanno, Yoshihiko ^a   Witt, Martje ^a   Okada, Hirokazu ^a   Nemoto, Hironori ^a   Sugahara, Soichi ^a   Nakamoto, Hidetomo ^a   Suzuki, Hiromichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Corticosteroid; IgA nephropathy; Warfarin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CREATININE; PREDNISOLONE; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; BIOPSY; BLOOD PRESSURE; CHILD; CREATININE; FEMALE; GLOMERULONEPHRITIS, IGA; GLUCOCORTICOIDS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PREDNISOLONE; PROTEINURIA; WARFARIN;

EID: 0037365630     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101570300006     Document Type: Article

References (13)

1. Caraman PL, Azoulay E, Kessler M, Zerrouki BM, Mayeux D, Bene MC, Faure GC. Mucosal infections and allergy in IgA nephropathy. A retrospective study. Association des Nephrologues de l'Est de la France. Contrib Nephrol 1993;104:24-30.
2. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999;353:883-7.
3. D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992;20:315-23.
4. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 1995;111:184-92; discussion 192-3.
5. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 1998;53:1209-16.
6. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996;72:237-42.
7. Donadio JJ, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999;10:1772-7.
8. Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol 1999;10:101-9.
9. Okada H, Suzuki H, Konishi K, Sakaguchi H, Saruta T. Histological alterations in renal specimens as indicators of prognosis of IgA nephropathy. Clin Nephrol 1992;37:235-8.
10. Kanno Y, Okada H, Saruta T, Suzuki H. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000;54:360-5.
11. Yoshikawa N, Ito H. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy - is it relevant for adult patients? Nephrol Dial Transplant 1999;14:1097-9.
12. Waldo FB, Wyatt RJ, Kelly DR, Herrera GA, Benfield MR, Kohaut EC. Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone. Pediatr Nephrol 1993;7:529-32.
13. Hamazaki T, Tateno S, Shishido H. Eicosapentaenoic acid and IgA nephropathy (letter). Lancet 1984;I:1017-8.